🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Xijing Hospital of Digestive Diseases clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Xijing Hospital of Digestive Diseases as lead sponsor. Synced 26 Sep 2026
20Current trials
17Recruiting now
12Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Xijing Hospital of Digestive Diseases is the lead sponsor of 20 current clinical trials in our China register. 17 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Fenofibrate, UDCA and Ursodeoxycholic Acid. The most-studied condition is Primary Biliary Cholangitis (PBC).

ClinicalTrials.gov trials by status

  • Recruiting1785%
  • Active, closed210%
  • By invitation15%

Trials by phase

  • Not applicable735%
  • Phase 4420%
  • Phase 3420%
  • Observational210%
  • Phase 2/3210%
  • Phase EARLY_PHASE115%
01

Clinical trials sponsored by Xijing Hospital of Digestive Diseases

20 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Optimization of taVNS Intervention Strategies for Refractory Constipation
NCT07344402 · Refractory Constipation
Not applicable Recruiting 2025-09 China
Effect of Questionnaires and Feedback on the Patient Compliance for Endoscopic Surveillance After ESD
NCT06092281 · ClinicalTrials.gov ↗ · Patient Compliance
Not applicable Recruiting 2023-10 China
Selection and Efficacy-Influencing Factors of First-Line Biologic Agents in Moderate-to-Severe Ulcerative Colitis
NCT06962020 · ClinicalTrials.gov ↗ · Ulcerative Colitis (UC)
Observational Recruiting 2025-04 China
Fenofibrate in Primary Biliary Cholangitis: a Real World Study
NCT06755151 · ClinicalTrials.gov ↗ · Primary Biliary Cholangitis (PBC)
Phase 3 Recruiting 2024-01 China
FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
NCT07296458 · ClinicalTrials.gov ↗ · Primary Biliary Cholangitis (PBC)
Phase 3 Recruiting 2025-12 China
Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
NCT05749822 · ClinicalTrials.gov ↗ · Primary Biliary Cholangitis
Phase 2/3 Recruiting 2023-02 China
Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis(UPRISE)
NCT07550673 · ClinicalTrials.gov ↗ · Acute Severe Ulcerative Colitis
Phase 4 Recruiting 2026-04 China
Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia
NCT07182890 · ClinicalTrials.gov ↗ · Functional Dyspepsia, Probiotics, Depression
Phase 4 Recruiting 2025-09 China
Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia
NCT07187492 · ClinicalTrials.gov ↗ · Functional Dyspepsia, Probiotics, Depression
Phase 4 Recruiting 2025-09 China
Comparison of Different Operations for Siewert Type II Adenocarcinoma of Esophagogastric Junction
NCT05356520 · ClinicalTrials.gov ↗ · Siewert Type II Adenocarcinoma of Esophagogastric Junction
Not applicable Recruiting 2022-05 China
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study
NCT06755541 · ClinicalTrials.gov ↗ · Primary Biliary Cholangitis (PBC)
Phase 3 Recruiting 2024-01 China
Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
NCT05751967 · ClinicalTrials.gov ↗ · Primary Biliary Cholangitis
Phase 3 Recruiting 2023-02 China
Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation
NCT06221722 · ClinicalTrials.gov ↗ · Constipation - Functional, Refractory Constipation, Fluoxetine
Observational Recruiting 2023-11 China
Transcranial Alternating Current Stimulation for Refractory Constipation With Somatic Symptom Disorder
NCT07323407 · ClinicalTrials.gov ↗ · Functional Constipation (FC), Somatic Symptom Disorder (DSM-5), Refractory Constipation
Not applicable Recruiting 2025-08 China
Full-time RDI for ESD: Impact on Major Adverse Events and Procedure Time
NCT07401303 · ClinicalTrials.gov ↗ · Early Gastric Cancer or Gastric Adenoma
Not applicable Recruiting 2026-03 China
Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)
NCT06365424 · ClinicalTrials.gov ↗ · Primary Biliary Cholangitis
Phase 2/3 Recruiting 2017-04 China
Advanced Adenoma Detection With 3D Imaging Device During Colonoscopy
NCT06924489 · ClinicalTrials.gov ↗ · Colorectal Adenoma, Colorectal Polyps
Not applicable Recruiting 2025-06 China
The Efficacy of Hyperbaric Oxygen-assisted Treatment for ASUC and Refractory IBD
NCT07257588 · ClinicalTrials.gov ↗ · Ulcerative Colitis
Not applicable By invitation 2024-09 China
Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment
NCT06523764 · ClinicalTrials.gov ↗ · Helicobacter Pylori Infection Chronic Gastrit
Phase 4 Active, closed 2024-11 China
Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)
NCT07104201 · ClinicalTrials.gov ↗ · Primary Biliary Cholangitis (PBC)
Phase EARLY_PHASE1 Active, closed 2025-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Xijing Hospital of Digestive Diseases trials

12 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Xijing Hospital of Digestive Diseases trials

21 conditions
Primary Biliary Cholangitis (PBC)4Refractory Constipation3Primary Biliary Cholangitis3Functional Dyspepsia2Probiotics2Depression2Anxiety2Patient Compliance1Ulcerative Colitis (UC)1Helicobacter Pylori Infection Chronic Gastrit1Acute Severe Ulcerative Colitis1Siewert Type II Adenocarcinoma of Esophagogastric Junction1Constipation - Functional1Fluoxetine1fMRI1Functional Constipation (FC)1Somatic Symptom Disorder (DSM-5)1Early Gastric Cancer or Gastric Adenoma1Ulcerative Colitis1Colorectal Adenoma1Colorectal Polyps1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2017

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Primary Biliary Cholangitis (PBC)

SponsorTrials
Cascade Pharmaceuticals1

Sponsors with the most current trials registered for this condition.

06

Questions about Xijing Hospital of Digestive Diseases trials

How many clinical trials does Xijing Hospital of Digestive Diseases sponsor?

Xijing Hospital of Digestive Diseases is the lead sponsor of 20 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Xijing Hospital of Digestive Diseases trials recruiting?

Yes. 17 of its 20 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Xijing Hospital of Digestive Diseases testing?

Its current trials name 12 drugs and biologicals as interventions. The most frequent are Fenofibrate (6), UDCA (2), Ursodeoxycholic Acid (2), Amoxicillin (1) and Bismuth potassium citrate (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.